Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

27 Jul 2026, 22:51 UTC · 4h ago

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Recursion Pharmaceuticals (RXRX) is projected to see a 37.64% year-over-year decline in revenue for its upcoming quarterly release. — A significant double-digit decline in revenue typically signals deteriorating business fundamentals or lost market share.
-0.60
2
Recursion Pharmaceuticals' upcoming quarterly EPS is projected at -$0.25, a 39.02% improvement over the previous year. — While still negative, a narrowing loss suggests improving cost management or operational efficiency.
+0.30
3
Recursion Pharmaceuticals currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating indicates a neutral outlook with no strong immediate catalyst for price movement.
+0.00